{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:23:22Z","timestamp":1788942202068,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P36435"],"award-info":[{"award-number":["P36435"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.euo.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T21:14:02Z","timestamp":1715807642000},"page":"1166-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models"],"prefix":"10.1016","volume":"7","author":[{"given":"Michael","family":"Gutmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Herek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Vician","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"N\u00f6ssing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Brettner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Lemberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Grausenburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Batlogg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Baumfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Prantl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Oszwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Wasinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0014-1658","authenticated-orcid":false,"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Englinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.05.001_b0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2022.03.009","article-title":"Molecular and pharmacological bladder cancer therapy screening: discovery of clofarabine as a highly active compound","volume":"82","author":"Ertl","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.05.001_b0010","first-page":"1329","article-title":"Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs","volume":"34","author":"Bagley","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.euo.2024.05.001_b0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2967\/jnumed.111.090407","article-title":"Stratification of nucleoside analog chemotherapy using 1-(2\u2032-deoxy-2\u2032-18F-fluoro-\u03b2-D-arabinofuranosyl)cytosine and 1-(2\u2032-deoxy-2\u2032-18F-fluoro-\u03b2-L-arabinofuranosyl)-5-methylcytosine PET","volume":"53","author":"Lee","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euo.2024.05.001_b0020","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1158\/1078-0432.CCR-07-4521","article-title":"Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study","volume":"14","author":"Veltkamp","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.05.001_b0025","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.euo.2024.05.001_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-020-01626-9","article-title":"Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta-analysis of the clinicopathological features and survival outcomes","volume":"20","author":"Gu","year":"2020","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.euo.2024.05.001_b0035","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.3109\/10428194.2013.763397","article-title":"Oral clofarabine for relapsed\/refractory non-Hodgkin lymphomas: results of a phase 1 study","volume":"54","author":"Abramson","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.euo.2024.05.001_b0040","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00280-010-1376-z","article-title":"Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer","volume":"67","author":"Bonate","year":"2011","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124001159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:01:41Z","timestamp":1778868101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124001159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":8,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2588931124001159"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofarabine Has a Superior Therapeutic Window as compared to Gemcitabine in Preclinical Bladder Cancer Models","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}